Du är här

2015-10-02

Galapagos NV: Galapagos raises €1.2 million through warrant exercises

Mechelen, Belgium; 2 October 2015 - Galapagos NV (Euronext&NASDAQ: GLPG)
announced a share capital increase arising from warrant exercises.

As a result of warrant exercises, Galapagos issued 118,260 new ordinary shares
on 25 September 2015, for a total capital increase (including issuance
premium) of €1,198,094.00.

Pursuant to the rules of the warrant exercise program of Galapagos' Executive
Committee adopted in 2013, Executive Committee members automatically are
committed to exercise a minimum number of warrants, subject to certain
conditions. Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants
and two other Executive Committee members exercised an aggregate amount of
5,000 warrants.

In accordance with Belgian transparency legislation[1], Galapagos notes that
its total share capital currently amounts to €211,045,322.22; the total
number of securities conferring voting rights is 39,012,842, which is also
the total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 2,869,192, which equals the total number of
voting rights that may result from the exercise of these warrants. Galapagos
does not have any convertible bonds or shares without voting rights
outstanding.

About Galapagos

Galapagos (Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule
and antibody programs in cystic fibrosis, inflammation, and other
indications. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable safety profile in
both the DARWIN 1 and 2 trials in RA. In the field of cystic fibrosis,
AbbVie and Galapagos signed a collaboration agreement to develop and
commercialize molecules that address mutations in the CFTR gene. Potentiator
GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the
pre-clinical candidate stage. GLPG1205, a first-in-class inhibitor of GPR84
and fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully
proprietary, first-in-class inhibitor of autotaxin, has shown favorable
safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More info atwww.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, VP Corporate Communications&IR
Tel: +1-781-460-1784
ir@glpg.com

Forward-looking statements

This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates," "may,"
"will," "could," "stands to," "continues," "we believe," "we intend," as well
as similar expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or future
results, financial conditions, performance or achievements expressed or
implied by such forward-looking statements. Among the factors that may result
in differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities, regulatory
approval requirements and estimating the commercial potential of our product
candidates. A further list and description of these risks, uncertainties and
other risks can be found in the company's Securities and Exchange Commission
filing and reports, including in the company's prospectus filed with the SEC
on May 14, 2015 and future filings and reports by the company. Given these
uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
unless required by law or regulation.
---------------------------------------[1]Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#1956421

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.